Lancet Neurol:支架再狭窄率明显高于内膜剥脱

2018-08-08 杨中华 脑血管病及重症文献导读

内膜剥脱和支架目的在于降低颈动脉动脉粥样硬化性疾病患者的长期卒中风险。这些症状性颈动脉狭窄手术的随机试验发现,与内膜剥脱手术相比,支架的卒中风险更高,特别是老年患者,但是心梗、颅神经麻痹和手术部位血肿的风险更低。

内膜剥脱和支架目的在于降低颈动脉动脉粥样硬化性疾病患者的长期卒中风险。这些症状性颈动脉狭窄手术的随机试验发现,与内膜剥脱手术相比,支架的卒中风险更高,特别是老年患者,但是心梗、颅神经麻痹和手术部位血肿的风险更低。过了围手术期以后,支架和内膜剥脱预防卒中复发的作用是相同的,但是每一种手术之后颈动脉长期的再狭窄率是不同的。更加重要的是,手术后残留狭窄或再狭窄是否会增加卒中的风险,目前尚未被回答。

国际颈动脉支架研究(International Carotid Stenting Study,ICSS)是截止到目前为止最大型的随机试验,比较了症状性颈动脉狭窄采取颈动脉剥脱手术或支架手术的疗效。以前曾经报道过ICSS的10年随访结果,显示每一种手术在预防致死性或残疾性卒中(主要终点)方面是等效的。并且没有发现长期严重(>=70%)再狭窄率的差异。

2018年7月来自英国的Leo H Bonati等在Lancet Neurology上公布了ICSS事先设定的二次分析结果,目的在于定量随机后高达10年的中度-严重再狭窄(>=50%)的长期风险,探究两种手术后再狭窄是否会导致高风险的卒中复发,另外还探讨了再狭窄的危险因素。

ICSS是一项随机对照试验,共来自欧洲、澳大利亚、新西兰和加拿大50个三级医院参与。纳入的患者为年龄>=40岁的症状性颈动脉狭窄(>=50%)的患者,按照1:1的比例随机接受支架或内膜剥脱手术。再狭窄定义为经治动脉>=50%狭窄(中度)或>=70%狭窄(严重)或闭塞。

从2001年5月到2008年10月,共纳入了1713例患者,支架组855例,内膜剥脱组858例。在这些患者中,1530例(支架组737例,内膜剥脱组793例)采用了超声随访,平均4年(IQR 2.3-5.0)。支架组和内膜剥脱组至少中度再狭窄(>=50%)例数分别为274例和217例;累积5年风险分别为40.7%和29.6%(未调整HR 1.43, 95% CI 1.21–1.72; p<0.0001)。至少中度再狭窄(>=50%)者发生同侧卒中的风险:在全部患者人群(HR 3.18, 95% CI 1.52–6.67; p=0.002)和内膜剥脱组(5.75, 1.80–18.33; p=0.003)皆明显高于无再狭窄者;支架组未达到显着性(2.03, 0.77–5.37; p=0.154; p=0.10 for interaction with treatment)。在两个治疗组中,严重再狭窄(>=70%)或随后的卒中风险没有差异。

最终作者认为至少中度(>=50%)再狭窄更常见于支架组,并且在全部患者中这会增加同侧卒中的风险。需要进一步探讨支架和内膜剥脱患者再狭窄介导卒中风险的差别。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000532, encodeId=1aba200053269, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Dec 28 22:47:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708473, encodeId=94641e08473d3, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri Mar 15 18:47:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829740, encodeId=bdda1829e402a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 18 15:47:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486204, encodeId=fa29148620400, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Aug 10 06:47:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-12-28 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000532, encodeId=1aba200053269, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Dec 28 22:47:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708473, encodeId=94641e08473d3, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri Mar 15 18:47:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829740, encodeId=bdda1829e402a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 18 15:47:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486204, encodeId=fa29148620400, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Aug 10 06:47:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000532, encodeId=1aba200053269, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Dec 28 22:47:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708473, encodeId=94641e08473d3, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri Mar 15 18:47:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829740, encodeId=bdda1829e402a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 18 15:47:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486204, encodeId=fa29148620400, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Aug 10 06:47:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2019-02-18 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=2000532, encodeId=1aba200053269, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Dec 28 22:47:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708473, encodeId=94641e08473d3, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Fri Mar 15 18:47:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829740, encodeId=bdda1829e402a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Feb 18 15:47:00 CST 2019, time=2019-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486204, encodeId=fa29148620400, content=<a href='/topic/show?id=15b93065283' target=_blank style='color:#2F92EE;'>#再狭窄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30652, encryptionId=15b93065283, topicName=再狭窄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf8f8090913, createdName=12498f1em10(暂无昵称), createdTime=Fri Aug 10 06:47:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]

相关资讯

Int J Nanomed:新型多孔纳米支架材料具有良好的生物相容性和新骨形成能力

据预测,随着全世界预期寿命的增加,对合成生物医学材料的需求将变得越来越大,以修复或再生丧失、受伤或患病的组织。天然聚合物作为生物医学材料已广泛应用于再生医学领域。本研究通过将纳米多孔透辉石生物玻璃(nDPB)掺入glia-din(GL)基质中,通过溶液压缩和颗粒浸出的方法制备了nDPB/GL复合材料(DGC)的大纳米多孔支架。 结果表明,DGC支架具有200-500μm的良好相互连接的大孔和

GUT:腔内金属支架与塑料支架相比对于肠壁坏死引流治疗不具有优越性

研究认为金属支架相比于塑料支架在肠壁坏死引流中的优势不显著。为了减少金属制剂导致的不良事件,患者症状消失后应尽快取出支架

CHC2018丨支架贴壁不良的腔内影像学评价

皮冠状动脉腔内血管成形术、新型药物涂层支架等的广泛应用,显著降低支架内再狭窄发生,但伴发的支架贴壁不良引起学者关注。CHC 2018大会上,温州医科大学附属第一医院单培仁博士针对支架贴壁不良的影像学评价进行了详细介绍。

Circ: Cardiovascular Interventions:瓣中瓣经导管肺动脉瓣置换患者生物瓣框架的目的性折断

初步经验表明,BPV框架目的性折断有助于瓣中瓣TPVR后达到更大的ID和更好的血液动力学状况。

支架脱载-嵌顿于桡动脉-外科切开取出(每一场并发症都是医生的梦魇)

患者女性,79岁,因“反复胸闷、胸痛1+年”于2016年05月20日入住我院心内科。1年前患者活动后出现胸闷、胸痛,经休息可缓解,后反复发作,每次经休息或含服“速效救心丸”后缓解,考虑“冠心病?”

J Dent Res:氟磷灰石修饰的支架材料上干细胞分化的信号转导通路

作者之前的报道显示,氟磷灰石(FA)修饰的羧基乙酸内脂(PCL)纳米纤维可作为成牙本质/成骨诱导的组织工程支架诱导干细胞的分化和矿化。这篇研究的目的是为了探讨影响这种分化和矿化过程的信号转导通路。